AGL 38.10 Decreased By ▼ -1.48 (-3.74%)
AIRLINK 128.12 Decreased By ▼ -3.10 (-2.36%)
BOP 6.88 Increased By ▲ 0.07 (1.03%)
CNERGY 4.53 Decreased By ▼ -0.18 (-3.82%)
DCL 8.07 Decreased By ▼ -0.37 (-4.38%)
DFML 39.30 Decreased By ▼ -2.17 (-5.23%)
DGKC 78.25 Decreased By ▼ -3.84 (-4.68%)
FCCL 31.45 Decreased By ▼ -1.65 (-4.98%)
FFBL 70.20 Decreased By ▼ -2.67 (-3.66%)
FFL 11.95 Decreased By ▼ -0.31 (-2.53%)
HUBC 107.50 Decreased By ▼ -3.24 (-2.93%)
HUMNL 13.55 Decreased By ▼ -0.96 (-6.62%)
KEL 4.85 Decreased By ▼ -0.34 (-6.55%)
KOSM 7.50 Decreased By ▼ -0.11 (-1.45%)
MLCF 37.25 Decreased By ▼ -1.65 (-4.24%)
NBP 67.30 Increased By ▲ 3.29 (5.14%)
OGDC 187.51 Decreased By ▼ -5.31 (-2.75%)
PAEL 24.95 Decreased By ▼ -0.73 (-2.84%)
PIBTL 7.25 Decreased By ▼ -0.09 (-1.23%)
PPL 147.20 Decreased By ▼ -6.87 (-4.46%)
PRL 24.79 Decreased By ▼ -1.04 (-4.03%)
PTC 16.73 Decreased By ▼ -1.08 (-6.06%)
SEARL 79.30 Decreased By ▼ -3.00 (-3.65%)
TELE 7.38 Decreased By ▼ -0.38 (-4.9%)
TOMCL 32.35 Decreased By ▼ -1.11 (-3.32%)
TPLP 8.18 Decreased By ▼ -0.31 (-3.65%)
TREET 16.61 Decreased By ▼ -0.01 (-0.06%)
TRG 56.25 Decreased By ▼ -1.15 (-2%)
UNITY 27.72 Increased By ▲ 0.21 (0.76%)
WTL 1.32 Decreased By ▼ -0.05 (-3.65%)
BR100 10,239 Decreased By -265.6 (-2.53%)
BR30 30,232 Decreased By -994 (-3.18%)
KSE100 96,251 Decreased By -1828.8 (-1.86%)
KSE30 30,009 Decreased By -549.4 (-1.8%)

Health-care products maker Johnson & Johnson won US approval to sell a new HIV drug called Intelence for patients with resistance to other therapies, US officials said on Friday. The drug, also known as TMC125 or etravirine, is a new member of the family of AIDS-fighting drugs called non-nucleoside reverse transcriptase inhibitors (NNRTI).
More than two dozen drugs are approved for fighting the deadly HIV virus. Patients need new options because HIV can mutate to resist existing treatments.

Copyright Reuters, 2008

Comments

Comments are closed.